Mesoblast (#ASX: $MSB) Cash on hand at March 31, 2020 was US$60.1M (A$97.3M). 9-months revenues up 113% to US$31.5 million;  loss after tax down 34% to US$45.3M from US$69.1M pcp. May 2020, pro forma cash on hand ~US$150M (A$235M). https://t.co/vEM6OlpiOO. #medicine #stocks. https://t.co/quT5u1lwz5